Type of tumor	Immunohistochemical characteristics
Breast adenocarcinoma, NOS	>95% CK7+, <5% CK20+, >70% ESR+, 60% PGR+, >80% GATA3+, 50% GCDF15+, 50% Mammaglobin+
Lung adenocarcinoma	>90% CK7+, 5% CK20+, 80% TTF1+, 80% Napsin A+
Mesothelioma (non sarcomatous)	>75% CK7+, <5% CK20+, >90% CK5/6+, >90% CK5+, >90% Calretinin+, 90% Podoplanin+, >80% WT1+, 70% Vimentin+, 50% BAP1+, 50% CA125+, 10% EpCam+, 2% P40+, 1% mCEA
Endometrial adenocarcinoma, NOS	>95% CK7+, <5% CK20+, >70% ESR+, >70% PGR+, 15% mCEA+
Endocervical adenocarcinoma, NOS	>95% CK7+, 5% CK20+, >80% mCEA+, <30% ESR+, <20% PGR
Ovarian (non-mucinous) adenocarcinoma, NOS	>95% CK7+, <10% CK20+, >95% PAX8+, >95% EpCam+, >70% ESR+, >70% Ca125+, 60% WT1+, 90% Napsin A+ (clear cell type)
Cholangiocarcinoma	>90% CK7+, 30% CK20+, 60% OCT4+, 60% CDH17+, >60% mCEA, 50% BAP1
Thyroid carcinoma (non-medullary)	100% CK7+, 0% CK20, >95% TTF1+, >90% Thyreoglobulin+, >95% PAX8+, 70% BRAF
Thyroid carcinoma medullary	100% CK7+, 0% CK20, 100% Calcitonin+, >95% Synaptophysin+, 95% ChromograninA+, 85% mCEA+, >95% TTF1+, <10% Thyreoglobulin+
Gastric adenocarcinoma (subset)	<80% CK7+, <70% CK20, <60% mCEA+, <60% CDX2+
Pancreas adenocarcinoma (subset)	>95% CK7+, <60% CK20+, >90% BAP1+